ReviewBiomarkers in T-cell therapy clinical trials
Section snippets
Principles for development and use of biomarkers in clinical research
The primary objectives of clinical trials are the evaluation of the safety and clinical efficacy of novel therapeutic agents. Although the first of these goals is generally straightforward, measuring clinical efficacy of adoptive T-cell treatments targeting cancer is often challenging for a variety of reasons that relate to heterogeneity in patient clinical and immune status, as well as to the biological nature and intrinsic variability of the therapeutic modality. With these considerations in
Integration of biomarkers from preclinical studies to clinical application
Early evidence for product efficacy and bioactivity in clinical trials is of critical importance to guide the further development of the candidate product. Accordingly, there is growing interest to identify sensitive, robust and meaningful biomarkers that may provide relevant insights into the clinical development process 8, 9. In addition to informing decisions on whether to advance new agents into clinical trials, preclinical biomarker studies commonly evaluate mechanistic aspects of the
T-cell therapy clinical trials
The essential objectives of immunotherapy as a treatment for cancer are (i) to mediate potent anti-tumor immunity leading to disease remission and (ii) to establish long-lasting immunity to target antigens and tumor. For the past 20 years, immunotherapy approaches have principally focused on the evaluation of therapeutic vaccine-based approaches to target cancer (10). In the vast majority of cases, such approaches have not been successful, with reviews of the many clinical trials indicating
Biomarkers in T-cell therapy trials
Unlike the majority of anti-cancer therapeutics in clinical trials, adoptive T-cell therapy is unique in that the therapeutic is a biological entity whose physiological status is critical to mediate the desired therapeutic effect. Thus, for treatment to be efficacious, the transferred T cells must be present and functional. Furthermore, to protect the patient against recurrent disease, the infused cells and their progeny probably must be capable of long-term functional persistence.
Classes of biomarkers for T-cell trials
We may classify biological parameters that are likely to be important for T-cell bioactivity as follows: (i) presence, (ii) relevant phenotypes and functional competence, (iii) systemic impact on patient biology and (iv) patient immune responses to the infused product.
Flow cytometry-based approaches
The antigenic specificity of T cells is associated with the α/β heterodimer, which is part of the TcR complex. Thus, assays to detect specific TcR α/β pairs present on infused cells can be used to quantify infused T-cell products. For products that are composed of CD8 T cells with a defined antigenic specificity, MHC (major histocompatibility complex) class I and class II multimers (tetramers, pentamers, dextramers) have been used to detect and quantify infused cells with a defined antigenic
Conclusions
Promising results from recent clinical trials suggest that the potential of T-cell immunotherapy as an effective approach to target cancer is finally beginning to be realized 18, 46, 47. As discussed above, a wide variety of biomarkers have been developed and are available to evaluate T-cell presence, persistence, phenotype and function as well as the impact of the treatment on the patient biology, disease status and immune function. Because it is unlikely that clinical efficacy of T-cell
Acknowledgments
Effort and publication costs for this work were supported in part by the human Immunology Core (HIC) of the University of Pennsylvania.
Disclosure of interests: MK has patents and potential royalties based on commercialization of CAR-based technologies; he is a member scientific advisory board for Adaptive Biotechnologies. SFL reports no commercial, proprietary or financial interest in the products or companies described in this article.
References (89)
- et al.
Comprehensive assessment of T-cell receptor beta-chain diversity in alphabeta T cells
Blood
(2009) Natural killer cell-based immunotherapeutic strategies
Cytotherapy
(2005)- et al.
A phase 1 trial of donor lymphocyte infusions expanded and activated ex vivo via CD3/CD28 costimulation
Blood
(2006) - et al.
Adoptive transfer of unselected or leukemia-reactive T-cells in the treatment of relapse following allogeneic hematopoietic cell transplantation
Semin Immunol
(2010) - et al.
Administration of latent membrane protein 2-specific cytotoxic T lymphocytes to patients with relapsed Epstein-Barr virus-positive lymphoma
Clin Lymphoma Myeloma
(2006) - et al.
Cytotoxic T lymphocyte therapy with donor T cells prevents and treats adenovirus and Epstein-Barr virus infections after haploidentical and matched unrelated stem cell transplantation
Blood
(2009) - et al.
Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen
Blood
(2009) - et al.
Adoptive transfer of chimeric antigen receptor re-directed cytolytic T lymphocyte clones in patients with neuroblastoma
Mol Ther
(2007) - et al.
Antitransgene rejection responses contribute to attenuated persistence of adoptively transferred CD20/CD19-specific chimeric antigen receptor redirected T cells in humans
Biol Blood Marrow Transplant
(2010) - et al.
Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells
Blood
(2008)
High avidity myeloid leukemia-associated antigen-specific CD8+ T cells preferentially reside in the bone marrow
Blood
CARs on track in the clinic
Mol Ther
Adoptive immunotherapy with allodepleted donor T-cells improves immune reconstitution after haploidentical stem cell transplantation
Blood
Transition of late-stage effector T cells to CD27+ CD28+ tumor-reactive effector memory T cells in humans after adoptive cell transfer therapy
Blood
A distinct subset of self-renewing human memory CD8+ T cells survives cytotoxic chemotherapy
Immunity
Improving adoptive T cell therapy by targeting and controlling IL-12 expression to the tumor environment
Mol Ther
Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired
Blood
Levels of peripheral CD4(+)FoxP3(+) regulatory T cells are negatively associated with clinical response to adoptive immunotherapy of human cancer
Blood
B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells
Blood
Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19
Blood
Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2
Mol Ther
Treatment of chronic lymphocytic leukemia with genetically targeted autologous T cells: case report of an unforeseen adverse event in a phase I clinical trial
Mol Ther
Analysis of transgene-specific immune responses that limit the in vivo persistence of adoptively transferred HSV-TK-modified donor T cells after allogeneic hematopoietic cell transplantation
Blood
Immune responses to transgene and retroviral vector in patients treated with ex vivo-engineered T cells
Blood
“MIATA”: minimal information about T cell assays
Immunity
Beyond six colors: a new era in flow cytometry
Nat Med
Cytopenia and leukocyte recovery shape cytokine fluctuations after myeloablative allogeneic hematopoietic stem cell transplantation
Haematologica
Monitoring cytokine profiles during immunotherapy
Immunotherapy
Gene signature in melanoma associated with clinical activity: a potential clue to unlock cancer immunotherapy
Cancer J
Global transcriptional analysis for biomarker discovery and validation in cellular therapies
Mol Diagn Ther
An integrative paradigm to impart quality to correlative science
J Transl Med
Defining the critical hurdles in cancer immunotherapy
J Transl Med
Recommendations from the iSBTc-SITC/FDA/NCI Workshop on Immunotherapy Biomarkers
Clin Cancer Res
Cancer immunotherapy: moving beyond current vaccines
Nat Med
Therapeutic cancer vaccines: are we there yet?
Immunol Rev
Enhancing the clinical activity of granulocyte-macrophage colony-stimulating factor-secreting tumor cell vaccines
Immunol Rev
Immunotherapy of malignant brain tumors
Immunol Rev
Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer
Cancer
Cytokine induced killer cells as adoptive immunotherapy strategy to augment graft versus tumor after hematopoietic cell transplantation
Exp Opin Biol Ther
Invariant natural killer T cell-based immunotherapy for cancer
Immunotherapy
Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1
J Clin Oncol
Adoptive immunotherapy for cancer: building on success
Nat Rev Immunol
Adoptive T cell therapy for cancer in the clinic
J Clin Invest
Optimization of human T-cell expansion ex vivo using magnetic beads conjugated with anti-CD3 and Anti-CD28 antibodies
J Immunother
Cited by (6)
Engineered T Cell Therapies from a Drug Development Viewpoint
2019, EngineeringCitation Excerpt :We also emphasize the critical roles of biomarkers in guiding the drug development process. Furthermore, we discuss the impact of advanced technologies and computational tools in identifying better cancer-specific targets, novel CAR binding domains, and biomarkers that can be used to maximize clinical outcomes and minimize toxicity [28,29]. Similar to conventional drug development, target identification is the first step in a gene-to-drug reverse pharmacology approach (Figs. 2 and 3, Table 1) [30,31].
Immune evasion in cell-based immunotherapy: unraveling challenges and novel strategies
2024, Journal of Biomedical ScienceCurrent flow cytometry methods for the clinical development of immunomodulatory biologics
2016, AAPS Advances in the Pharmaceutical Sciences SeriesAdoptive T-cell therapy: A need for standard immune monitoring
2015, Immunotherapy